Cleveland Biolabs, Inc. engages in the discovery, development, and commercialization of products for cancer treatment and protection of normal tissues from radiation and other acute stresses. The company?s products include Protectan CBLB502, a radioprotectant molecule with multiple medical and defense applications for reducing injury from acute stresses, such as radiation and chemotherapy by mobilizing various natural cell protecting mechanisms, including inhibition of apoptosis, reduction of oxidative damage, and induction of factors that induce protection and regeneration of stem cells in bone marrow and intestine; Protectan CBLB612, a modified lipopeptide mycoplasma that acts as a stimulator and mobilizer of hematopoietic stem cells to peripheral blood, providing hematopoietic recovery during chemotherapy and during donor preparation for bone marrow transplantation; and Curaxins, small molecules that are intended to destroy tumor cells by simultaneously targeting two regulators of apoptosis. Cleveland Biolabs has strategic alliance with The Cleveland Clinic Foundation; a research agreement with Roswell Park Cancer Institute to develop its cancer and radioprotectant drug candidates; a strategic partnership with ChemBridge Corporation to access a chemical library of approximately 1,000,000 compounds; and a cooperative research and development agreement with the Armed Forces Radiobiology Research Institute. The company was founded in 2003 and is headquartered in Buffalo, New York
